Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $26

Benzinga · 3d ago
Mizuho analyst Graig Suvannavejh maintains Immix Biopharma (NASDAQ:IMMX) with a Outperform and raises the price target from $15 to $26.